Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cybin Inc (NY: CYBN ) 0.2640 UNCHANGED Official Closing Price Updated: 8:00 PM EDT, Jun 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Cybin Inc < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Featured Presenter at Upcoming H.C. Wainwright Neuro Perspectives Virtual Conference June 20, 2024 Via Investor Brand Network Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference June 19, 2024 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Strategic Appointment of Dr. Atul Mahableshwarkar June 11, 2024 Via Investor Brand Network Exposures Product Safety Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development June 11, 2024 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at Interdisciplinary Conference on Psychedelic Research 2024 May 29, 2024 Via Investor Brand Network Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024 May 29, 2024 From Cybin Inc. Via Business Wire BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Slated to Present at Upcoming Alliance Global Partners Healthcare Company Showcase May 14, 2024 Via Investor Brand Network Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase May 14, 2024 From Cybin Inc. Via Business Wire PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Issues Corporate Update, Eyes Runway for Upcoming Clinical Milestones May 06, 2024 Via Investor Brand Network Exposures Product Safety Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones May 06, 2024 From Cybin Inc. Via Business Wire PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at the 27th Annual Milken Institute Global Conference April 25, 2024 Via Investor Brand Network Exposures Product Safety Cybin to Participate at the 27th Annual Milken Institute Global Conference April 25, 2024 From Cybin Inc. Via Business Wire PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Research Published in “Journal of Medicinal Chemistry” April 18, 2024 Via Investor Brand Network Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry April 18, 2024 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Notice of Patent Grant for CYB003 Breakthrough MDD Therapy Program April 16, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder April 16, 2024 From Cybin Inc. Via Business Wire PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at Bloom Burton & Co. Healthcare Conference April 10, 2024 Via Investor Brand Network Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference April 10, 2024 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming Public Ventures Discovery Day March 18, 2024 Via Investor Brand Network Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas March 18, 2024 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Initiates Phase 2 Study of CYB004 for Generalized Anxiety Disorder March 15, 2024 Via Investor Brand Network Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder March 15, 2024 From Cybin Inc. Via Business Wire Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO March 15, 2024 Via AB Newswire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Meeting with FDA to Review End of Phase 2 Study, Proposed Phase 3 Program March 14, 2024 Via Investor Brand Network Exposures Product Safety Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design March 14, 2024 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives Share CYB003 Program Update During Webcast March 13, 2024 Via Investor Brand Network Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder March 13, 2024 From Cybin Inc. Via Business Wire Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 March 12, 2024 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming TD Cowen Health Care Conference February 27, 2024 Via Investor Brand Network Cybin to Present at the TD Cowen 44th Annual Health Care Conference February 27, 2024 From Cybin Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.